TiumBio Co., Ltd. (KOSDAQ:321550)

South Korea flag South Korea · Delayed Price · Currency is KRW
12,000
+1,400 (13.21%)
At close: Apr 27, 2026
170.27%
Market Cap 366.19B
Revenue (ttm) 12.29B
Net Income (ttm) -17.36B
Shares Out 29.97M
EPS (ttm) -640.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,282,371
Average Volume 569,603
Open 10,890
Previous Close 10,600
Day's Range 10,620 - 12,320
52-Week Range 4,400 - 13,480
Beta -0.45
RSI 66.44
Earnings Date May 15, 2026

About TiumBio

TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 321550
Full Company Profile

Financial Performance

In 2025, TiumBio's revenue was 12.29 billion, an increase of 80.92% compared to the previous year's 6.79 billion. Losses were -17.36 billion, -15.90% less than in 2024.

Financial Statements

News

There is no news available yet.